{"entity":{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","aka":["Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc."],"tldr":"Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023.","summary":"Spectrum Pharmaceuticals, latterly based in Boston after years in Henderson, Nevada, marketed a haematology portfolio (Zevalin, Folotyn, Beleodaq, Marqibo and Evomela) that it sold to Acrotech Biopharma in 2019 to concentrate on two development programmes: poziotinib, an EGFR and HER2 exon 20 inhibitor that received a complete response letter in 2022, and eflapegrastim (Rolvedon), a long-acting G-CSF for chemotherapy-induced neutropenia approved by the FDA in September 2022. Assertio Holdings acquired the company in 2023. It appears on OnCo as one of the most frequent industry sponsors of phase 3 cancer trials on the registry.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals","links":[{"label":"ClinicalTrials.gov: trials led by Spectrum Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["supportive-care","targeted-therapy"],"technologies":[],"targets":[],"drugs":["belinostat","pralatrexate"],"companies":["acrotech-biopharma"],"institutions":[],"pathways":[],"terms":["neutropenia"],"trials":["nct04570423"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.spectrumpharm.com","stage":"acquired","investors":[],"funding":[]},"route":"/companies/spectrum-pharmaceuticals/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/"},{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/"},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/"},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/"}],"company":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/"}],"term":[{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"}],"trial":[{"id":"nct04172597","kind":"trial","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","route":"/trials/nct04172597/"},{"id":"nct03744715","kind":"trial","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","route":"/trials/nct03744715/"},{"id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/"},{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","route":"/trials/nct02659514/"}]}}